Mercurna

Mercurna is a Netherlands-based preclinical-stage biotechnology company developing targeted mRNA therapeutics for inflammatory and immune-mediated disorders. The company leverages its proprietary modular nanomedicine platform, which combines tissue-specific targeting ligands (such as kidney-homing peptides) with optimized lipid nanoparticle (LNP) delivery systems and de-immunized mRNA payloads. This approach enables precise, localized protein expression directly within diseased cells, minimizing systemic side effects. Mercurna's lead program, mCura1, is a kidney-targeted mRNA therapeutic designed to treat glomerulonephritis and chronic kidney disease. Additionally, the company is advancing collaborative programs for delayed graft function, congenital anemia, cystinosis, and cystic fibrosis.